Who are ▶︎ STRM.BIO's investors?

▶︎ STRM.BIO's investors include Ascension Ventures, Breakout Labs, Breakout Ventures, Delos Capital, NYBC Ventures, KdT Ventures.

▶︎ STRM.BIO

Founded 2019 · 18 employees on LinkedIn · 6 known investors

Find your way into ▶︎ STRM.BIO

489 people in our graph share verified history with the ▶︎ STRM.BIO team — schools, employers, funds. One of them is your warm intro.

Tim Xiaounlockedknows Michael Luther · together at ▶︎ STRM.BIO (overlapped)

knows the team · via ▶︎ STRM.BIO

×3knows the team · via MassBio

×7knows the team · via Astellas Pharma

STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients. The company operates in the biotech sector, focused on advancing gene therapy for patients worldwide.

Biotech Deep Tech Healthtech Longevity Medical Devices

Founders & leadership

Michael Luther CEOMichael Luther has held executive roles across life science operations, from early-stage companies to multinational pharmaceutical and contract research organizations, with international management experience across the UK, Canada, Japan, and India. His background spans drug discovery and development, particularly in oncology and immunology, along with strategic planning, business development, and board governance in public, private, and academic institutions.

Investors · 6

Ascension Ventureslisted by Ascension VenturesSaint Louis · $10M – $20M

Breakout Labslisted by Breakout Labs

How we know: Breakout Labs's portfolio page · the VCSheet dataset · Not right? Tell us

Breakout Ventureslisted by Breakout VenturesSan Francisco · $500K – $6M

How we know: Breakout Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Delos Capitallisted by Delos CapitalCambridge

NYBC Ventureslisted by NYBC VenturesNew York

KdT VenturesreportedAustin · $500K – $3M

How we know: the VCSheet dataset · Not right? Tell us

Founder mafia

2 people who came through ▶︎ STRM.BIO went on to found or lead other companies.

Jon RowleyScientific Advisory Board MemberFounded RoosterBio Michael LutherCEOFounded Bantam Pharmaceutical

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2022	$2.1M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does ▶︎ STRM.BIO do?: STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients. The company operates in the biotech sector, focused on advancing gene therapy for patients worldwide.
Who are ▶︎ STRM.BIO's investors?: ▶︎ STRM.BIO's investors include Ascension Ventures, Breakout Labs, Breakout Ventures, Delos Capital, NYBC Ventures, KdT Ventures.